← Back to Search

Other

Telehealth for Hepatitis C Treatment

N/A
Recruiting
Led By Jens Rosenau, MD
Research Sponsored by Jens Rosenau
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
History of hepatitis C
Be older than 18 years old
Must not have
Subjects with impaired capacity to provide informed consent
HIV or HBV co-infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trialwill investigate if providing HCV treatment through a P&P office using telemedicine can help people get treatment without needing to travel to a specialist's office.

Who is the study for?
This trial is for individuals on probation or parole with a history of hepatitis C who will be supervised at the office for at least 5 months. They must have health insurance, be able to consent to the study, and have a life expectancy over one year. It's not open to those without active hepatitis C infection, pregnant or breastfeeding women, people co-infected with HIV/HBV, or those with severe liver cirrhosis.
What is being tested?
The study tests if telehealth services in a probation and parole office can effectively link patients to hepatitis C care and treatment compared to previous methods. Participants receive consultations from HCV experts via telemedicine during regular appointments without extra travel.
What are the potential side effects?
Since this trial focuses on service delivery rather than medication side effects are not detailed here. However, typical HCV treatments may include headaches, fatigue, nausea which would be monitored by healthcare providers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had hepatitis C in the past.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am unable to understand or sign the consent form by myself.
Select...
I am co-infected with HIV or hepatitis B.
Select...
My liver is severely damaged, with a score indicating advanced disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
HCV treatment uptake rate of HCV RNA positive participants
Secondary study objectives
Determine visit adherence
HCV treatment uptake rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with Hepatitis CExperimental Treatment1 Intervention
Participants will be clients at the Lexington Probation and Parole office who are Hepatitic C positive.

Find a Location

Who is running the clinical trial?

AbbVieIndustry Sponsor
1,029 Previous Clinical Trials
521,380 Total Patients Enrolled
110 Trials studying Hepatitis C
32,679 Patients Enrolled for Hepatitis C
Jens RosenauLead Sponsor
1 Previous Clinical Trials
657 Total Patients Enrolled
1 Trials studying Hepatitis C
657 Patients Enrolled for Hepatitis C
Jens Rosenau, MDPrincipal InvestigatorUniversity of Kentucky
1 Previous Clinical Trials
657 Total Patients Enrolled
1 Trials studying Hepatitis C
657 Patients Enrolled for Hepatitis C

Media Library

Telehealth in Parole/Probation Office (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05413785 — N/A
Hepatitis C Research Study Groups: Participants with Hepatitis C
Hepatitis C Clinical Trial 2023: Telehealth in Parole/Probation Office Highlights & Side Effects. Trial Name: NCT05413785 — N/A
Telehealth in Parole/Probation Office (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05413785 — N/A
Hepatitis C Patient Testimony for trial: Trial Name: NCT05413785 — N/A
~5 spots leftby Dec 2024